コンテンツへスキップ
Merck
  • Formulation considerations in the design of topical, polymeric film-forming systems for sustained drug delivery to the skin.

Formulation considerations in the design of topical, polymeric film-forming systems for sustained drug delivery to the skin.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V (2015-01-18)
Kit Frederiksen, Richard H Guy, Karsten Petersson
要旨

Polymeric film-forming systems (FFSs) are potential drug delivery systems for topical application to the skin. The FFSs form thin and transparent polymeric films in situ upon solvent evaporation. Their application convenience and cosmetic attributes, superior to conventional semi-solids, may offer improved patient compliance. This study represents the first phase of an investigation into the use of FFSs for prolonged dermal drug delivery. FFS formulations were distinguished based on their ability to sustain the release of betamethasone 17-valerate (BMV) in vitro over 72 h. The effect of film-forming polymer (hydrophilic: hydroxypropyl cellulose (Klucel™ LF); hydrophobic: polymethacrylate copolymers (Eudragit® NE and Eudragit® RS), and polyacrylate copolymer (Dermacryl® 79) was first determined, and then the impact of incorporation of plasticisers (triethyl citrate, tributyl citrate, and dibutyl sebacate) was examined. The Klucel film released a significantly higher amount of BMV than the hydrophobic FFS, 42 versus 4 μg/cm(2), respectively. The release was increased when a plasticiser was incorporated, and with higher enhancement ratios achieved with the more lipophilic plasticisers. In conclusion, the results show that FFSs can sustain drug release (hence representing useful systems for prolonged dermal therapy) and emphasise the importance of the formulation on drug delivery, with the type of polymer being of greatest significance.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
酢酸ナトリウム 三水和物, ACS reagent, ≥99%
Sigma-Aldrich
メタクリル酸メチル, contains ≤30 ppm MEHQ as inhibitor, 99%
Sigma-Aldrich
酢酸ナトリウム 三水和物, ReagentPlus®, ≥99.0%
Sigma-Aldrich
酢酸ナトリウム 三水和物, puriss., meets analytical specification of Ph. Eur., BP, USP, FCC, E262, 99.0-101.0% (calc. to the dried substance), ≤0.00002% Al
Sigma-Aldrich
クエン酸トリエチル, ≥98.0% (GC)
Sigma-Aldrich
クエン酸トリエチル, ≥99%, FCC, FG
Sigma-Aldrich
酢酸ナトリウム 三水和物, BioUltra, ≥99.5% (NT)
Sigma-Aldrich
セバシン酸ジブチル, ≥97.0% (GC)
Sigma-Aldrich
クエン酸トリブチル, ≥97.0%
Sigma-Aldrich
セバシン酸ジブチル, technical grade
Sigma-Aldrich
酢酸ナトリウム 三水和物, SAJ first grade, ≥98.5%
Sigma-Aldrich
酢酸ナトリウム 三水和物, BioXtra, ≥99.0%
Sigma-Aldrich
酢酸ナトリウム 三水和物, JIS special grade, ≥99.0%
USP
クエン酸トリブチル, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
酢酸ナトリウム 三水和物, meets USP testing specifications
Sigma-Aldrich
メタクリル酸メチル, SAJ first grade, ≥99.0%
Supelco
クエン酸トリエチル, Pharmaceutical Secondary Standard; Certified Reference Material
メタクリル酸メチル, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
酢酸ナトリウム 三水和物, ≥99.0%, suitable for amino acid analysis
Supelco
セバシン酸ジブチル, Pharmaceutical Secondary Standard; Certified Reference Material